ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Cost-effectiveness analysis of endoscopic ultrasound as a first-line staging tool for patients with non-small-cell lung cancer
Endoscopy
◽
10.1055/s-0031-1292140
◽
2011
◽
Vol 43
(S 03)
◽
Author(s):
L Lai
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Endoscopic Ultrasound
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
Related Documents
Cited By
References
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
PharmacoEconomics
◽
10.1007/s40273-021-01022-9
◽
2021
◽
Author(s):
Yong-Jin Kim
◽
Mark Oremus
◽
Helen H. Chen
◽
Thomas McFarlane
◽
Danielle Fearon
◽
...
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Egfr Mutation
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Journal of Medical Economics
◽
10.1080/13696998.2019.1570221
◽
2019
◽
Vol 22
(4)
◽
pp. 344-349
◽
Cited By ~ 11
Author(s):
Weiting Liao
◽
Jiaxing Huang
◽
David Hutton
◽
Qiu Li
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
Value in Health
◽
10.1016/j.jval.2018.09.016
◽
2018
◽
Vol 21
◽
pp. S3
Author(s):
M.S. Holleman
◽
M.J. Al
◽
C.A. Uyl-de Groot
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Egfr Mutation
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
First‐Line Durvalumab in Addition to Etoposide and Platinum for Extensive‐Stage Small Cell Lung Cancer: A U.S.‐Based Cost‐Effectiveness Analysis
The Oncologist
◽
10.1002/onco.13954
◽
2021
◽
Author(s):
Shen Lin
◽
Shaohong Luo
◽
Dian Gu
◽
Meiyue Li
◽
Xin Rao
◽
...
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
◽
Extensive Stage
Download Full-text
Faculty Opinions recommendation of First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.736170538.793563121
◽
2019
◽
Author(s):
Alexandru Grigorescu
Keyword(s):
United States
◽
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
Cancer
◽
10.1002/cncr.32368
◽
2019
◽
Vol 125
(20)
◽
pp. 3526-3534
◽
Cited By ~ 18
Author(s):
XiaoMin Wan
◽
Xia Luo
◽
ChongQing Tan
◽
XiaoHui Zeng
◽
YuCong Zhang
◽
...
Keyword(s):
United States
◽
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
ClinicoEconomics and Outcomes Research
◽
10.2147/ceor.s128371
◽
2017
◽
Vol Volume 9
◽
pp. 505-518
◽
Cited By ~ 7
Author(s):
Kaisa Taipale
◽
Katherine B Winfree
◽
Mark Boye
◽
Mickael Basson
◽
Ghassan Sleilaty
◽
...
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Maintenance Treatment
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis from A UK Healthcare Perspective
Value in Health
◽
10.1016/j.jval.2017.08.006
◽
2017
◽
Vol 20
(9)
◽
pp. A399
◽
Cited By ~ 1
Author(s):
X Hu
◽
DP Goldman
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Healthcare Perspective
◽
Effectiveness Analysis
Download Full-text
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
ClinicoEconomics and Outcomes Research
◽
10.2147/ceor.s25923
◽
2012
◽
pp. 31
◽
Cited By ~ 13
Author(s):
Alain Vergnenègre
◽
Ray
◽
christos chouaid
◽
Grossi
◽
Bischoff
◽
...
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Maintenance Treatment
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand
Lung Cancer
◽
10.1016/j.lungcan.2018.04.003
◽
2018
◽
Vol 120
◽
pp. 91-97
◽
Cited By ~ 2
Author(s):
Chulaporn Limwattananon
◽
Supon Limwattananon
◽
Onanong Waleekhachonloet
◽
Thananan Rattanachotphanit
Keyword(s):
Lung Cancer
◽
Cost Effectiveness
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Policy Options
◽
Small Cell Lung
◽
First Line
◽
Effectiveness Analysis
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close